How does tirzepatide dosing work? Titration first, maintenance second.
Tirzepatide is a dual GIP/GLP-1 receptor agonist that works by activating two incretin hormone receptor pathways simultaneously. It slows gastric emptying, reduces appetite signaling, and promotes insulin secretion in a glucose- dependent manner. The combination produces greater appetite suppression and weight reduction than single-receptor GLP-1 agonists in head-to-head studies.
The clinical trial dosing protocol for tirzepatide (as studied in the SURMOUNT program) begins with a titration phase:
| Weeks | Dose | Phase |
|---|---|---|
| 1–4 | 2.5 mg once weekly | Titration (starting dose) |
| 5–8 | 5 mg once weekly | Titration / low maintenance |
| 9–12 | 7.5 mg once weekly | Titration (if escalating) |
| 13–16 | 10 mg once weekly | Titration / mid maintenance |
| 17–20 | 12.5 mg once weekly | Titration (if escalating) |
| 21+ | 15 mg once weekly | Maximum studied dose / maintenance |
Patients assigned to the 5 mg arm held at 5 mg after week 8; those in the 10 mg arm held at 10 mg after week 16. The slow titration is specifically designed to minimize gastrointestinal side effects (nausea, vomiting, diarrhea) that are dose-dependent and more severe if escalation is rapid.
Once a patient reaches their assigned or tolerated target dose and the dose is stable, they are in the maintenance phase — the dose does not continue escalating, but rather is sustained.
What the SURMOUNT trials show about maintenance-phase weight
SURMOUNT-1 enrolled 2,539 adults with obesity or overweight with at least one weight-related condition. After 72 weeks, participants receiving tirzepatide 15 mg achieved a mean body weight reduction of 20.9%. The 10 mg group achieved 19.5%, and the 5 mg group 15.0%, compared to 3.1% in the placebo group.
Importantly, most of the weight loss in the active groups occurred during the titration and early maintenance phases, with weight plateauing after approximately 36–52 weeks on the maintenance dose. This plateau is not a drug failure — it reflects the body reaching a new equilibrium at the lower body weight, where appetite and metabolic signals have been recalibrated.
Continuing the same maintenance dose generally sustains the achieved weight. The medication is not doing less work at that point; it is actively preventing the biological drive to regain weight that would otherwise occur.
At the maintenance dose, the medication is not doing less — it is actively holding back the body’s drive to regain the weight you worked to lose.
What happens to your weight when tirzepatide is stopped?
This is the most practically important question for long-term patients, and the evidence is unambiguous. GLP-1 and GIP receptor agonists like tirzepatide do not permanently alter body weight set points — they suppress appetite and slow gastric emptying for as long as the drug is present. When the drug is stopped, those effects reverse.
The most rigorous data comes from the STEP 1 extension study, which followed semaglutide patients (a related GLP-1 agonist) after the medication was stopped at 68 weeks. By 120 weeks — roughly one year after stopping — patients had regained approximately two-thirds of the weight they had lost. Most of the regain occurred within the first 20 weeks of stopping.
While that specific study involved semaglutide, the mechanism is the same class of drug and the same physiological dynamic applies to tirzepatide. Clinicians prescribing tirzepatide for weight management typically frame it as a long-term or indefinite therapy rather than a finite course — particularly for patients with significant obesity or weight-related health conditions.
Finding the right maintenance dose: individualization matters
The SURMOUNT trials used fixed dose assignments, but real-world clinical care is more flexible. Once a patient has achieved their weight management goal on a given dose, a clinician may consider:
- Holding at the effective dose: The simplest approach. If 10 mg produced the desired weight and is well tolerated, continuing at 10 mg is standard.
- Trying a lower maintenance dose: Some clinicians attempt a cautious step-down — for example, from 15 mg to 10 mg — after the patient has been stable for several months, monitoring weight closely. If weight trends upward, they return to the effective dose. There is limited trial data supporting specific step-down protocols; this is clinical judgment territory.
- Adjusting for tolerability or cost: Some patients experience persistent GI side effects at higher doses; a clinician may hold at a lower dose that is tolerated even if it achieves less weight loss, or explore compounded formulations at intermediate doses.
There is no validated minimum effective maintenance dose. The goal is the lowest dose that sustains the patient’s weight goals with acceptable tolerability — a target that requires monitoring weight trends over time, not a one-time prescription decision.
Compounded tirzepatide for maintenance: access and considerations
Patients using compounded tirzepatide through telehealth platforms during FDA shortage periods often have questions about long-term access. The practical considerations:
- Shortage status governs access: Compounded tirzepatide is legally available through licensed 503A pharmacies only when the branded product (Zepbound for weight management) is on the FDA shortage list. If shortage status changes, access pathways may change. Clinicians managing long-term patients should have a continuity plan.
- Branded access as an alternative: For patients who can access Zepbound through insurance or manufacturer assistance programs, branded tirzepatide may offer more regulatory certainty for a long-term maintenance prescription.
- Compounded formulation quality: For patients on maintenance who are using compounded tirzepatide long-term, the 503A pharmacy’s quality standards are especially important. PepScribe partners only with licensed 503A pharmacies in the United States — no hidden overseas supply chain.
Monitoring during tirzepatide maintenance
Reaching a maintenance dose does not mean clinical oversight stops. Responsible tirzepatide management during the maintenance phase includes:
- Weight tracking: Regular weight check-ins (at least monthly) to identify upward trends early and adjust the plan before significant regain occurs.
- Metabolic markers: For patients with weight-related metabolic conditions, periodic labs (fasting glucose, A1c, lipid panel) assess whether the metabolic benefits of weight loss are being maintained.
- GI tolerability: Some patients find GI side effects improve after several months on a stable dose; others find them persistent. Ongoing check-ins allow the clinician to adjust the dose or timing if tolerability is affecting quality of life.
- Muscle mass consideration: Significant caloric restriction with any weight management therapy can involve loss of lean mass. Clinicians may recommend resistance exercise and protein adequacy during both active loss and maintenance phases.
Frequently asked questions about tirzepatide maintenance dosage
What is a tirzepatide maintenance dose?
A tirzepatide maintenance dosage is the dose a patient continues on after reaching their weight management goal, intended to sustain the achieved weight rather than produce further reduction. The highest doses studied in clinical trials (10 mg and 15 mg weekly) were used for both active weight loss and maintenance in the SURMOUNT program.
What happens if you stop tirzepatide after reaching your goal weight?
Clinical evidence from GLP-1/GIP receptor agonist studies shows that stopping the medication is associated with significant weight regain, often most of what was lost, within one to two years. The STEP 1 trial extension with semaglutide (a related GLP-1 agonist) demonstrated approximately two-thirds of lost weight was regained within 68 weeks of stopping. Similar patterns are expected with tirzepatide.
Is maintenance dosing the same as the titration dose?
It can be. In the SURMOUNT-1 trial, patients who achieved 5 mg, 10 mg, or 15 mg weekly doses continued on those doses through the maintenance phase. Some clinicians work with patients to find the lowest dose that sustains weight, particularly for tolerability or cost reasons, but there is no universally established lower maintenance dose that has been validated in long-term trials.
Can a clinician adjust the dose during maintenance?
Yes. Dose adjustments during maintenance are clinical decisions based on individual response, tolerability, weight trends, and any side effects. A clinician who monitors your weight and biomarkers over time can make evidence-informed adjustments — this is not a set-and-forget medication.
Is compounded tirzepatide available for long-term maintenance?
Compounded tirzepatide availability depends on FDA shortage status for the branded products. During active shortage periods, licensed 503A pharmacies can legally prepare compounded tirzepatide. Patients on long-term maintenance should discuss supply continuity planning with their clinician as the regulatory landscape evolves.
What is the titration schedule for tirzepatide before reaching maintenance?
The SURMOUNT-1 titration schedule started at 2.5 mg weekly for 4 weeks, then increased by 2.5 mg every 4 weeks until reaching the target dose (5, 10, or 15 mg). Titrating slowly reduces gastrointestinal side effects. Maintenance begins once the target dose is reached and tolerated.